Metabolism / Research index
Semaglutide
Semaglutide is a GLP-1 receptor agonist investigated in clinical programs asking different questions. Body weight and cardiovascular events are different endpoints. Combining both into a single promise would remove the context needed to interpret the evidence and the product actually studied.
Names used in the literature: Semaglutide · Semaglutida
Read the evidence and its sources ↓That presentation is not part of this listing. Review the available options before adding a selection.
Semaglutide 5 mg
- Presentation
- 5 mg
- Catalog reference
- PMX-SEMA-5
Semaglutide 10 mg
- Presentation
- 10 mg
- Catalog reference
- PMX-SEMA-10
Availability and documentation await confirmation. Listed quantities identify catalog presentations, not instructions for use.
STEP 1: weight and trial context
STEP 1 enrolled 1,961 adults with overweight or obesity without diabetes. Mean weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo; both groups received a lifestyle intervention. Nausea and diarrhea were the most frequent adverse events with semaglutide, and more participants discontinued because of gastrointestinal events.
Sources: [1]
SELECT: a defined cardiovascular population
SELECT enrolled people with preexisting cardiovascular disease and overweight or obesity, without diabetes. Over a mean 39.8-month follow-up, the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5% with semaglutide and 8.0% with placebo. These results concern that population and the investigated medicine.
Sources: [2]
Follow-up and presentation are separate questions
A later SELECT analysis described weight and body-measurement changes over longer follow-up. It adds information about duration within that population, but does not verify the identity, contents or stability of a catalog vial. Evidence concerning an active ingredient and assessment of a finished product are different levels of evidence.
Sources: [3]
Questions about this reference
Are semaglutide salts automatically equivalent?
No. FDA distinguishes semaglutide sodium and semaglutide acetate from the ingredient used in approved medicines. An abbreviated catalog name does not resolve that chemical difference or establish equivalence.
Is a cardiovascular outcome the same as weight loss?
No. SELECT assessed cardiovascular events in people with existing disease. Weight change alone does not demonstrate that outcome or justify assigning it to another product or population.
Sources and original reading
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Content updated: . How this content is prepared and checked.
Understand before comparing